ORIC - NASDAQ
ORIC Pharmaceuticals, Inc.
$8.04
+5.6%ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotORIC Pharmaceuticals, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
ORIC Pharmaceuticals, Inc. Cash Flow Statement
ORIC • NASDAQ
| ORIC Pharmaceuticals, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||
-129.5M | -127.8M | -100.7M | -89.1M | -78.7M | -73.7M | -26.9M | -21.4M | -22M | |
1.2M | 1.1M | 1M | 966K | 897K | 970K | 1M | 903K | 900K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 299K | 0.0 | 0.0 | 0.0 | |
0.0 | 20.2M | 15.2M | 14.5M | 12.9M | 5.3M | 1.1M | 469K | 217.0 | |
20.3M | -8.1M | -6.1M | -1M | 1.4M | 19.8M | 8K | 15K | 2M | |
-5.5M | 2M | 4.9M | -445K | 4.1M | 2M | 1.2M | -707K | 95K | |
-113.4M | -112.7M | -85.7M | -75.1M | -59.5M | -45.3M | -23.5M | -20.7M | -20.8M | |
INVESTING ACTIVITIES | |||||||||
-712K | -1.2M | -849K | -2.1M | -939K | -667K | -768K | -525K | -486K | |
(0.0) | (0.0) | (0.0) | (2.1M) | (1.4M) | (0.0) | (0.0) | (0.0) | (0.0) | |
-399.8M | -251.9M | -239.2M | -238.1M | -69.6M | -225.5M | (0.0) | (0.0) | (0.0) | |
252.5M | 275.2M | 196.7M | 131M | 229M | 10M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | -2.1M | -1.4M | 193K | 0.0 | 17K | 194K | |
-148M | (22.1M) | -43.4M | -109.2M | (158.4M) | -216M | -768K | -508K | -292K | |
FINANCING ACTIVITIES | |||||||||
247.7M | 125M | 85M | 25M | 50M | 271.3M | 0.0 | 0.0 | 260K | |
0.0 | 1.5M | 658K | 225K | -866K | -20.8M | 32K | 79K | 0.0 | |
247.7M | 126.5M | 85.7M | 25.2M | 49.1M | 250.5M | 70.8M | 38M | 260K | |
CASH FLOW SUMMARY | |||||||||
-13.7M | 36M | -43.4M | -159.2M | 148M | -10.7M | 46.5M | 16.8M | -20.9M | |
59.9M | 23.9M | 67.3M | 226.5M | 78.4M | 89.2M | 42.6M | 25.8M | 46.7M | |
46.2M | 59.9M | 23.9M | 67.3M | 226.5M | 78.4M | 89.2M | 42.6M | 25.8M | |
-114.1M | -113.9M | -86.5M | -77.2M | -60.5M | -45.9M | -24.3M | -21.2M | -21.3M |
SEC Filings
ORIC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 04, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 18, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 31, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 23, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 13, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 |
Related Guides
Continue your ORIC research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.